Partners4Access

Partners4Access comment on the new Eurordis Position Paper on access to orphan drugs

Partners4Access (P4A), the specialists in orphan drug access, are launching a weekly newsletter focussing on key developments in the rare diseases and orphan drugs market access landscape.

Sophie Schmitz, Managing Partner of Partners4Access, the specialists in orphan drug access, is presenting at the 8th annual meeting of the World Orphan Drug Congress in Barcelona on November 15, 2017 on Gene Therapy.

Partners4Access (P4A) the specialists in orphan drug access, are presenting 3 posters at the International Society for Pharmacoeconomics and Outcomes Research's (ISPOR) 20th European Congress in Glasgow from 4th to 8th November 2017.

Partners4Access (P4A), the specialists in orphan drug access, are launching a new webinar series, in line with their expanding activities in gene therapy.

Partners4Access launch an innovative Professional Access Coaching for Excellence Service

Partners4Access (P4A) the specialists in orphan drug access, has appointed two new analysts to their European team, in line with their expanding activities in gene therapy.

Partners4Access will attend the Festival of Genomics in Boston on October 3rd, 2017. Sophie Schmitz, Managing Partner at P4A will be there meeting representatives of the research and patient community as well as the pharmaceutical industry.

Partners4Access Managing Partner Sophie Schmitz attended the World Orphan Drug Congress in Washington and reports insights from the Glybera case.

London team strengthened to drive further launch support for the biotechnology industry. Continued focus is 'Orphan Drug Solutions' a partnership approach to ensuring a successful global launch.